Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients-Reference-Cited by-同舟云学术

Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients

Published:2020-07-29 Issue:1 Volume:31 Page:226-234
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Nishimura Kenichi¹,Hara Ryoki¹,Umebayashi Hiroaki²,Takei Syuji³,Iwata Naomi⁴,Imagawa Tomoyuki⁵,Shimizu Masaki⁶,Tomiita Minako⁷,Seko Noriko⁸,Kitawaki Tetsuji⁸,Yokota Shumpei⁹

Affiliation:

1. Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan

2. Department of Rheumatology and Infectious Disease, Miyagi Children’s Hospital, Sendai, Japan

3. School of Medical and Dental Sciences Pediatrics, Kagoshima University Graduate, Kagoshima, Japan

4. Department of Infection and Immunology, Aichi Children’s Health and Medical Center, Obu, Japan

5. Department of Infection and Immunology, Kanagawa Children’s Medical Center, Yokohama, Japan

6. Department of Pediatrics, Kanazawa University Hospital, Kanazawa, Japan

7. Department of Pediatrics, Pediatric Allergy and Rheumatology Center, National Hospital Organization Shimoshizu National Hospital, Chiba, Japan

8. Novartis Pharma KK, Tokyo, Japan

9. Children’s Intractable Disease Rheumatism Center, Fuji Toranomon Orthopedics Hospital, Shizuoka, Japan

Funder

Novartis Pharma AG, Basel, Switzerland

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14397595.2020.1783163

Reference50 articles.

1. Juvenile idiopathic arthritis

2. Systemic JIA as an Autoinflammatory Disease

3. Takei S, Yamashita S, Kato T. Nation-wide survey for patients with juvenile idiopathic arthritis in Japan. Annual Report on Children with Chronic Refractory Diseases from the Japanese Ministry of Health, Labor and Welfare 2008. p. 102–13.

4. Clinical analysis of 570 cases with juvenile rheumatoid arthritis: Results of a nationwide retrospective survey in Japan

5. Clinical practice guidance for juvenile idiopathic arthritis (JIA) 2018

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience;Pediatric Rheumatology;2024-03-19

2. Canakinumab in the treatment of systemic juvenile idiopathic arthritis: a retrospective single center study in China;Frontiers in Pediatrics;2024-03-14

3. The safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter study;Expert Opinion on Biological Therapy;2023-11-17

4. Treatment for macrophage activation syndrome associated with systemic juvenile idiopathic arthritis in Japan;International Journal of Rheumatic Diseases;2023-03-27

5. Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data;Frontiers in Pediatrics;2023-02-22